Akero Therapeutics Appoints Mark Iwicki to its Board of Directors

SAN FRANCISCO, Dec. 6, 2018 -- (Healthcare Sales & Marketing Network) -- Akero Therapeutics Inc., a biotechnology company developing transformational treatments for non-alcoholic steatohepatitis (NASH) and other serious metabolic diseases, today announced... Biopharmaceuticals, Personnel Akero Therapeutics, non-alcoholic steatohepatitis
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news